Skip to content

Clinical trials

Phase 2 Myelodysplastic Syndromes trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myelodysplastic Syndromes Phase: Phase 2 Country / region: Germany Clear all

55 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20034
20071
20083
20092
20103
20114
20121
20134
20145
20156
20163
20193
20202
20213
20225
20232
20252

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed27
Terminated15
Recruiting4
Active, not recruiting4
Withdrawn3
Enrolling by invitation1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals7
Celgene4
Heinrich-Heine University, Duesseldorf4
University of Leipzig4
European Organisation for Research and Treatment of Cancer - EORTC3
Technische Universität Dresden3
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA2
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH2
Kiadis Pharma2
Universitätsklinikum Hamburg-Eppendorf2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myelodysplastic Syndromes55
Leukemia, Myeloid, Acute16
Leukemia, Myelomonocytic, Chronic9
Anemia7
Anemia, Refractory, with Excess of Blasts5
Cytopenia3
Hematologic Neoplasms3
Precursor Cell Lymphoblastic Leukemia-Lymphoma3
Graft vs Host Disease2
Thrombocytopenia2

Trials

Showing 1 to 25 of 55. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.